Empress Therapeutics

How does Empress' genetics-first approach set us apart from others in the field? Our CEO, Jason Park, spoke to GenomeWeb about creating predictability and speed in drug discovery by using genetics to seek out and optimize drug-like molecules produced by microorganisms already within our bodies. He also reveals how far along the company is on its trajectory to the clinic. 📚 Read the story to get the scoop: https://lnkd.in/g6yGDiMS #Chemilogics #smallmolecule #drugdiscovery #AI #machinelearning #microbiome 

We are excited to share that Empress Therapeutics has been named to C&EN’s annual list of #10StartUpsToWatch! This recognition highlights our unique #Chemilogics platform that applies the power of genetics, coevolution, and AI to discover chemistry-based drug leads and disease targets from inside the human body - bringing predictability & speed to small molecule drug discovery. See more here: https://lnkd.in/gunzUhhJ #smallmolecule #drugdiscovery #AI #machinelearning #synbio #metagenomics

How is #AI transforming the business landscape of drug discovery? Join Empress's Chief Innovation Officer, Sabrina Yang, for a discussion on this topic at Genetic Engineering & Biotechnology News inaugural virtual summit, 𝗧𝗵𝗲 𝗦𝘁𝗮𝘁𝗲 𝗼𝗳 𝗔𝗜 𝗶𝗻 𝗗𝗿𝘂𝗴 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆. ➡️ Register for the free October 30th event: https://lnkd.in/gh8U2Zcb #Chemilogics #smallmolecule #drugdiscovery #machinelearning #drugdevelopment #drugdiscovery #biotech #business

Context matters when it comes to microbial communities in our bodies, especially in the gut. Different diets and other lifestyle factors can impact whether a person responds to probiotics and other treatments. We learned a lot from Francesca Gazzaniga, who joined us at Empire HQ for the latest #EMPIREexternal talk. The assistant professor at Harvard Medical School and Massachusetts General Hospital, shared her insights into the role of gut microbiomes on immune function in cancer. And she was a fellow fan of the concept of harnessing co-evolution and the genetic chemistry inside our bodies to create new medicines, saying that figuring out what our bacteria are doing to our immune system to make our body respond may be the key to discovering more safe and effective treatments with fewer immune-related side effects. 🎥 See what else she had to say in this short video. #microbiology #chemistry #microbiome #guthealth #immunology #cancer #smallmolecule #drugdiscovery #AI #machinelearning #Chemilogics

Revisiting our very first episode with Jason Park, CEO at Empress Therapeutics. In this clip, Jason speaks specifically about his unique experience working within the unique business model of Flagship Pioneering and how the idea for Empress (which raised $50 million in 2023) was born. Jason discusses the company's mission, goals and visions for the future while we also get views on Empress' scientific thesis from Professor Jim Collins (Massachusetts Institute of Technology) and Leon Henderson-MacLennan, MD, FACP Henderson MacLennan (inThought Research) Listen to the full episode here: https://lnkd.in/giHB9acS Available on Apple, Spotify or wherever you listen. Original Episode Date: November 21, 2023

✨ Big screen stars under the stars: Our summer Movie Night was a success, with perfect weather setting the stage for an enjoyable evening at the fabulous Arsenal on the Charles Life Sciences Campus watching the film IF in great company with tasty snacks. 🍿 🙌🏽 Thanks to our setup crew and all #TeamEmpress attendees for making it a night to remember!

Not only did our cofounder and CIO Sabrina Yang share her entrepreneurial journey at the 2024 BTBA 12th Annual Symposium, she also discussed more about founding and growing Empress Therapeutics. Sabrina played key roles in the foundational exploration and scientific discovery that created our #Chemilogics platform as well as building the team – from interviewing and hiring the company’s first employees and advisors to recruiting esteemed academic leaders to the Scientific Advisory Board and hiring top talent to the senior leadership team. Now #TeamEmpress is ~45 people, and Sabrina says, “It really takes a team, and I am proud of what we have done and where we are going in our mission to make small molecule drug discovery faster and more predictable.”

Being a pioneer in your field comes with certain challenges. Just like innovations in recombinant DNA were required to unlock the generation of biologic protein-based drugs, we've had to invent new synthetic biology tools and methods to facilitate our access to a previously untapped universe of chemistry-based drug leads inside the human body. In this interview with BioPharma-Reporter, Empress's Head of Platform Development, Dawn Thompson, discusses overcoming the challenges involved in exploring the metagenome for new medicines, as well as its exciting potential. Read the Q&A here: https://lnkd.in/d_r4X49B #Chemilogics #smallmolecule #drugdiscovery #AI #machinelearning #synbio #metagenomics

Combining the versatility of small molecules with the programmability of biologic therapies, Empress is creating a recipe for novel drug discovery and development inspired by the chemistry already in our bodies. In this Scrip Emerging Company profile, Empress CEO and cofounder Jason Park talks to Joseph Haas about how the company's Chemilogics platform uses AI, synthetic biology and genetic engineering to find novel chemistry and drug targets to provide new therapies across a wide range of indications. Read it on Citeline: https://lnkd.in/dDFtc2Uw #inflammation #immunology #oncology #metabolicdisease #AI #geneticengineering #synbio #drugdevelopment #drugdiscovery #Chemilogics #chemistry #machinelearning #FlagshipFounded

There's nothing better than evolution to inform scientists about what works, through experiments of nature conducted over eons. We share Steven Gygi's excitement about the potential for harnessing insights from the medicinal chemists inside our bodies, and we were delighted to welcome the cell biologist and proteomics pioneer as a guest speaker for the #EMPIREexternal seminar series. The Harvard Medical School professor of Gygi Lab and Director of the Thermo Fisher Scientific Center for Multiplexed Proteomics spoke about his work creating a genome-scale map of the protein-protein interaction landscape in cells. We caught up with him afterwards for further insights into new technologies to better understand small molecule mechanisms of action. 🎥 See what he had to say in this short video. #smallmolecule #drugdiscovery #AI #machinelearning #chemistry #computationalbiology #Chemilogics #microbiome #microbiology #BioPlex #proteomics